Ventricular phosphodiesterase-5 expression is increased in patients with advanced heart failure and contributes to adverse ventricular remodeling after myocardial infarction in mice. - Wikidata - wikimedia - TriplyDB

Ventricular phosphodiesterase-5 expression is increased in patients with advanced heart failure and contributes to adverse ventricular remodeling after myocardial infarction in mice.

Ventricular phosphodiesterase-5 expression is increased in patients with advanced heart failure and contributes to adverse ventricular remodeling after myocardial infarction in mice.

http://www.wikidata.org/entity/Q30548444

about

The Wonders of Phosphodiesterase-5 Inhibitors: A Majestic History Novel Radioligands for Cyclic Nucleotide Phosphodiesterase Imaging with Positron Emission Tomography: An Update on Developments Since 2012 Phosphodiesterases maintain signaling fidelity via compartmentalization of cyclic nucleotides Therapeutic potential of PDE modulation in treating heart disease Targeting myocardial remodelling to develop novel therapies for heart failure: a position paper from the Working Group on Myocardial Function of the European Society of Cardiology Phosphodiesterases and cardiac cGMP: evolving roles and controversies Inhibition of type 5 phosphodiesterase counteracts β2-adrenergic signalling in beating cardiomyocytes The emperor's new clothes: PDE5 and the heart Sildenafil ameliorates left ventricular T-tubule remodeling in a pressure overload-induced murine heart failure model PDE5A suppression of acute beta-adrenergic activation requires modulation of myocyte beta-3 signaling coupled to PKG-mediated troponin I phosphorylation.Erectile dysfunction and heart failure: the role of phosphodiesterase type 5 inhibitors.Concerted regulation of cGMP and cAMP phosphodiesterases in early cardiac hypertrophy induced by angiotensin II Cardiac hypertrophy is not amplified by deletion of cGMP-dependent protein kinase I in cardiomyocytes.Sex, drugs, and trial design: sex influences the heart and drug responses PDE5 inhibitor efficacy is estrogen dependent in female heart disease.Differential regulation of PDE5 expression in left and right ventricles of feline hypertrophy models.Cardiac cyclic nucleotide phosphodiesterases: function, regulation, and therapeutic prospects.Oxidative stress regulates left ventricular PDE5 expression in the failing heart Cardiac Z-disc signaling network.cGMP-dependent protein kinases and cGMP phosphodiesterases in nitric oxide and cGMP action.Targeting cyclic nucleotide phosphodiesterase in the heart: therapeutic implications.Cyclic guanosine monophosphate signaling and phosphodiesterase-5 inhibitors in cardioprotection.Sildenafil does not improve cardiomyopathy in Duchenne/Becker muscular dystrophy.Is chronic inhibition of phosphodiesterase type 5 cardioprotective and safe? A meta-analysis of randomized controlled trials.Protein kinase G I and heart failure: Shifting focus from vascular unloading to direct myocardial antiremodeling effects.Conserved expression and functions of PDE4 in rodent and human heart.Increased cardiac myocyte PDE5 levels in human and murine pressure overload hypertrophy contribute to adverse LV remodeling Pressure-overload-induced subcellular relocalization/oxidation of soluble guanylyl cyclase in the heart modulates enzyme stimulation.Alteration of vascular reactivity in heart failure: role of phosphodiesterases 3 and 4.Mitigation of the progression of heart failure with sildenafil involves inhibition of RhoA/Rho-kinase pathway sGC{alpha}1 mediates the negative inotropic effects of NO in cardiac myocytes independent of changes in calcium handling The role of phosphodiesterase inhibitors in the management of pulmonary vascular diseases Prominent expression of phosphodiesterase 5 in striated muscle of the rat urethra and levator ani.Impact of sildenafil on echocardiographic indices of myocardial performance after the Fontan operation Differential expression of PDE5 in failing and nonfailing human myocardium Right ventricular cyclic nucleotide signaling is decreased in hyperoxia-induced pulmonary hypertension in neonatal mice.PDE5 inhibitors as therapeutics for heart disease, diabetes and cancer Phosphodiesterase 5a Inhibition with Adenoviral Short Hairpin RNA Benefits Infarcted Heart Partially through Activation of Akt Signaling Pathway and Reduction of Inflammatory Cytokines Adenoviral short hairpin RNA therapy targeting phosphodiesterase 5a relieves cardiac remodeling and dysfunction following myocardial infarction Phosphodiesterase 4B mediates extracellular signal-regulated kinase-dependent up-regulation of mucin MUC5AC protein by Streptococcus pneumoniae by inhibiting cAMP-protein kinase A-dependent MKP-1 phosphatase pathway.

P2860

Q26741387-69DA0D0E-96AF-42BF-91F4-0A340C3E7D56 Q26746978-98D092D5-B901-443B-84FF-B9191A102E0A Q26860508-2BE1CC59-F46B-4ED0-962E-D197C855B4AF Q27005761-ACEC79ED-5F1F-4A04-9857-7EB21893CB89 Q27024879-A34D9524-DD49-4E62-B736-4C400BEFC578 Q27692588-DD47F859-616F-4FD9-A76C-965AA1526AE3 Q27967859-6694239C-F7F6-4C3F-9205-E15ECE445167 Q28543897-A8C5E873-59EE-4831-B325-A6587638E92B Q30385717-3F855B47-D2B8-46AE-BFDB-E2ADB152DBBB Q30494729-D55CF573-F1DD-4570-B11A-F7C7A62C5E4E Q33710298-22E68144-1B35-4070-8BCC-085E7E5F4B50 Q33769656-074223DD-D5EF-434C-AA34-E4866E8C1F56 Q33777629-6DC854DC-16B3-4482-B51C-CA07A04279D6 Q33872473-9B39E1D1-2D5B-491B-8586-B8BF4A173F67 Q33872491-6F443D1C-FA99-43D3-96FC-325205963FB5 Q33916555-8FCA09F6-D82E-4307-AE97-327E9771C1D1 Q33966155-7474C676-93AC-4964-B206-188465D58169 Q34105975-310AB5AA-31B5-413C-BEBA-D9B7F90404DB Q34160361-E5549256-8244-4727-8E70-C3E41392F77D Q34244951-096F37BE-54E7-4E52-9B01-35200ECDE7E2 Q34252901-66DC4C20-BE84-4A14-8FB0-8BDFB5DB0E9A Q34277031-6CB5E32C-F88B-40F6-A209-E854E86979B2 Q34315276-116FD287-A154-44BE-ADE8-45466568CE4E Q34364927-1892B4CD-EB8F-46A7-968B-AE4401163FD0 Q34421211-604946C7-57E8-46DC-8639-9E4552ED4F5B Q34548139-2F5DC508-56A6-4311-9524-4654A76D05CB Q34634339-FBBE3F1A-B4B8-4AD0-BC9D-84A9C5518AAB Q34686759-B8B884E1-03C5-4393-9F0C-4FE5C3B5307E Q34953389-5E4CA8CA-B355-49CF-994C-8D81CD711EC5 Q35056906-10655F72-E8C8-4F2E-A188-0D69258E2BDA Q35087054-97C56193-EB42-4412-9F03-FFA17AF70672 Q35156618-C4C0D171-240E-418B-93E3-54A9D8D47A91 Q35185989-6C4B0005-7C7A-4FB7-B4D7-F4DEBEEC5D9B Q35233153-4FA93FC2-62DD-495A-BB03-5D838DF2C98D Q35680934-ECB0FAFB-6C55-48B8-AD07-5D66FC2851F8 Q35749616-877E6DBE-06FA-4728-98E3-7B415051BFA3 Q35827798-4B0713B7-E172-4504-AA38-4F394535F5EB Q35879351-9F72AED8-F118-4ED1-86C5-B619C6884DA5 Q35994136-8E5E1BEA-9804-4E4E-9418-0904AE7907F5 Q36080545-B1828F3A-8010-4A37-B16D-E78311EB9AE4

P2860

Ventricular phosphodiesterase-5 expression is increased in patients with advanced heart failure and contributes to adverse ventricular remodeling after myocardial infarction in mice.

http://www.wikidata.org/entity/Q30548444

description

2009 nî lūn-bûn

@nan

2009 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Ventricular phosphodiesterase- ...... myocardial infarction in mice.

@ast

Ventricular phosphodiesterase- ...... myocardial infarction in mice.

@en

type

label

Ventricular phosphodiesterase- ...... myocardial infarction in mice.

@ast

Ventricular phosphodiesterase- ...... myocardial infarction in mice.

@en

prefLabel

Ventricular phosphodiesterase- ...... myocardial infarction in mice.

@ast

Ventricular phosphodiesterase- ...... myocardial infarction in mice.

@en

P1433

Q30548444-6CBCECB4-CC50-4C8D-A8B3-0969C53867C3

P1476

Q30548444-20C416B9-0433-4C2B-AC89-7FDE14211ED4

P2093

Q30548444-04113CCF-2B97-40DB-A265-C5937DAD18DF

Q30548444-1C66F9A4-12CE-4DDB-A619-92A799061BFF

Q30548444-31F762F8-48BA-458B-B238-F20507695D12

Q30548444-3947BEC8-D886-4D3C-809D-975BC24243DE

Q30548444-3D71483F-7BFB-4C71-A9E6-C36C74A25E26

Q30548444-43CBD028-9543-4C4E-8A42-F501E38A603A

Q30548444-44DAACD8-09C0-481C-A4B0-A6CF0A2F6799

Q30548444-498B4B0A-CC7D-49FA-B867-4CD554F8875E

Q30548444-4ECDE6A4-02A6-4626-80C8-BC78A0BA8818

Q30548444-4FCDD01E-6EF8-4CCF-A086-BE8D04E2A2A5

P2860

Q30548444-00571437-C659-4C36-98B9-D982E44992E6

Q30548444-038FAECB-6B9B-4CE8-A2B6-78FCFEA70D59

Q30548444-12E6299D-2210-46FF-A3BC-D4154E15B2F1

Q30548444-202E3E27-329E-4B31-9231-8CF2C1FE3BF5

Q30548444-26E1CE0A-C763-4591-9766-048A5BAEBA13

Q30548444-27D00213-C452-49B8-89B5-2179300DC39F

Q30548444-2B1CE98C-56F1-4ADB-BB36-29FA45726817

Q30548444-36709EFB-0A83-4299-A459-4839F2EAE328

Q30548444-380ED5F6-0AC6-487F-AFA2-B1D0A91A512A

Q30548444-3A403EFE-A95F-4690-BF74-0E90F9467B6B

P304

Q30548444-5EAE2D17-3C2F-4554-B898-E8ABF86FB0FC

P31

Q30548444-D63FB877-9F43-42E6-8DBE-43719634E8D7

P356

Q30548444-D1C5459D-B44B-429C-9CB4-D109F5D1031E

P407

Q30548444-B1654201-991A-4780-9157-15EE32B7DDF4

P433

Q30548444-392B445E-34CB-4B83-A049-B0CC15FD88DD

P478

Q30548444-7417DEC5-7997-4946-B0A6-0EEDCEA3D421

P577

Q30548444-3EE791A7-B473-4A15-A1D7-C0590F5FC5F5

P698

Q30548444-A52301C2-90A0-46D1-8CCA-E25B11CC95F9

P921

Q30548444-2B97DDE9-8FF0-49C4-AF2D-3771ACF4A431

Q30548444-5925DB28-297E-4C08-BEC9-E4430167E3F6

P932

Q30548444-26ACCB97-CD82-4129-A376-9A9B8D9146EB

P356

CIRCULATIONAHA.108.822072

P1433

P1476

Ventricular phosphodiesterase- ...... myocardial infarction in mice.

@en

P2093

Alfons Van Lommel

http://www.w3.org/2001/XMLSchema#string

An Van den Bergh

http://www.w3.org/2001/XMLSchema#string

Cornelius Busch

http://www.w3.org/2001/XMLSchema#string

Emmanuel Buys

http://www.w3.org/2001/XMLSchema#string

Erik Verbeken

http://www.w3.org/2001/XMLSchema#string

Glenn Marsboom

http://www.w3.org/2001/XMLSchema#string

Hilde Gillijns

http://www.w3.org/2001/XMLSchema#string

Ilse Lenaerts

http://www.w3.org/2001/XMLSchema#string

Johan Vanhaecke

http://www.w3.org/2001/XMLSchema#string

Karin Sipido

http://www.w3.org/2001/XMLSchema#string

P2860

Phosphodiesterase 4D deficiency in the ryanodine-receptor complex promotes heart failure and arrhythmias

Inhibition of cyclic GMP-binding cyclic GMP-specific phosphodiesterase (Type 5) by sildenafil and related compounds

Phosphodiesterase type 5 is highly expressed in the hypertrophied human right ventricle, and acute inhibition of phosphodiesterase type 5 improves contractility

Sildenafil improves exercise hemodynamics and oxygen uptake in patients with systolic heart failure.

Biochemistry and physiology of the natriuretic peptide receptor guanylyl cyclases.

Regulation of nitric oxide-sensitive guanylyl cyclase.

Structure, regulation, and function of mammalian membrane guanylyl cyclase receptors, with a focus on guanylyl cyclase-A.

Type 5 phosphodiesterase inhibition in heart failure and pulmonary hypertension.

Compartmentation of cyclic nucleotide signaling in the heart: the role of cyclic nucleotide phosphodiesterases.

Overview of PDEs and their regulation.

P304

408-416

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1161/CIRCULATIONAHA.108.822072

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

119

http://www.w3.org/2001/XMLSchema#string

P577

2009-01-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19139381

http://www.w3.org/2001/XMLSchema#string

P921

P932

3791110

http://www.w3.org/2001/XMLSchema#string